Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in Adults With Primary Sjogren's Syndrome
NCT04968912Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of nipocalimab in Sjogren's syndrome (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index at 24 weeks. Started Sep 2021; status: completed.
02
Drugs
nipocalimab
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT04968912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968912.